Investing Port

P/S	16.75
P/BV	8.48
EV/EBITDA	-10.44
EBITDA	-0.3062
Цена ао	48.89

Все параметры ⇨

		Недооценка Название Значение Оценка P/S 16.75 1 P/BV 8.48 1 P/E 0 EV/EBITDA -10.44 10	Эффективность Название Значение Оценка ROA, % -22.66 1 ROE, % -62.95 1
	Дивиденды Название Значение Оценка Div yield, % 0 DSI 0 0	Долг Название Значение Оценка Долг/EBITDA 0	Импульс роста Название Значение Оценка Рост прибыли, % 0 0 Рост цены акции, % 0 0 Рост дивидендов, % 0 0

Institutions	Объем	Доля, %
Hennion & Walsh, Inc	300	0
Bellevue Asset Management AG	4200990	6.07
Zeus Asset Management S.A.	2307	0
Security Investors, LLC	60870	0.09
Danske Bank Asset Management	120505	0.17
BNP Paribas Asset Management Luxembourg	652122	0.94
First Trust Portfolios L.P.	7106	0.01
Bellevue Group AG	4151002	5.99
Casdin Capital, LLC	1750000	2.53
The Variable Annuity Life Insurance Company	136789	0.2
Fidelity Management & Research Company LLC	6900591	9.96
Fidelity SelectCo, LLC	4628891	6.68
AXA Investment Managers UK Ltd	401644	0.58
Delaware Management Company	1869719	2.7
Goldman Sachs Asset Management International	21984	0.03
BNP Paribas Investment Partners.	292072	0.42
Munder Lee Investments Ltd	13052	0.02
Erste Asset Management GmbH	130500	0.19
Saint Olive Gestion	70000	0.1
Ghost Tree Capital, LLC	175000	0.25
Hennion & Walsh, Inc	300	0
MAVEN INVESTMENT PARTNERS US LTD	300000	0.43
Fidelity Management & Research Company LLC	2457751	3.55
Great Lakes Advisors, LLC	27708	0.04
ALPS Advisors Inc	123668	0.18
BlackRock Fund Advisors	2635868	3.81
SSGA Funds Management Inc	3043735	4.39
Penn Mutual Asset Management LLC	36312	0.05

ETF	Доля, %	Доходность за год, %	Дивиденды, %
SPDR S&P Biotech ETF	1.19	58.75	0.19
First Trust Amex Biotechnology Index	3.76	12.43	0.55
Direxion Daily S&P Biotech Bull 3x Shares	0.97	99.57	1.04
Virtus LifeSci Biotech Products ETF	2.89	24.86	0.79
ALPS Medical Breakthroughs ETF	2.23	34.21	0.50

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R\u002FR AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R\u002FR AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I\u002FII clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.